Puma Biotechnology Investor Presentation — May 2022

Document content

This presentation contains forward -looking statements, including statements regarding commercialization of NERLYNX® and the pote ntial indications

and development of our drug candidates. All forward -looking statements involve risks and uncertainties that could cause our actu al results to differ

materially from the anticipated results and expectations expressed in these forward -looking statements. These statements are bas ed on our current

expectations, forecasts and assumptions, and actual outcomes and results could differ materially from these statements due to a number of factors,

which include, but are not limited to, any adverse impact on our business or the global economy and financial markets, genera lly, from the global

COVID -19 pandemic, and the risk factors disclosed in our periodic and current reports filed with the Securities and Exchange Com mission from time to

time, including our Annual Report on Form 10 -K for the year ended December 31, 2021 and subsequent filings. Readers are cautione d not to place

undue reliance on these forward -looking statements, which speak only as of the date hereof. We assume no obligation to update th ese forward -looking

statements except as required by law.Forward -Looking Safe -Harbor Statement3

Copyright 2022 Puma BiotechnologyPUMA’s Pharmacy and Distributor Network

Others (VA, DOD)Hub Services

Specialty Pharmacy Network (SP)

Specialty Distributor Network (SD)

DMS Pharmaceutical Group

Copyright 2022 Puma Biotechnology~$41 Million net NERLYNX revenue in Q1’22

40.7Quarterly Net Revenue (in $MM)5

Copyright 2022 Puma Biotechnology2,680 Ex -factory bottles were sold in Q1’22

2,680Bottles Sold (SP + SD) by Quarter